CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?

Published: Thu, 8 Nov 2018 12:00:00 EST
Evidence suggests that sacubitril/valsartan may have antiarrhythmic effects. What does this mean for prevention of sudden death?
Circulation

Novel Anti-B-Cell Therapy Looks Promising in MS

Published: Thu, 18 Oct 2018 11:23:17 EDT
A new and novel oral therapy for multiple sclerosis, which inactivates rather than depletes B cells, has shown promising results in its first efficacy study.
Medscape Medical News

AAO 2018

Published: Thu, 18 Oct 2018 10:57:41 EDT
Read clinically focused news coverage of key developments from AAO 2018.
Medscape Ophthalmology
Displaying results 1-3 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Ziopharm’s R&D head joins Spectrum as CMO

Published: Thu, 18 Oct 2018 13:59:55 +0000
Ziopharm Oncology’s executive vice president of R&D, Francois Lebel, M.D., is moving to cancer drugmaker Spectrum Pharmaceuticals to serve as its chief medical officer effective Nov. 5.

Gilead, Aelix ally to trial HIV-suppressing combination

Published: Thu, 18 Oct 2018 10:38:27 +0000
Gilead has teamed up with Aelix Therapeutics to trial a combination designed to free people with HIV from the need to take antiretroviral drugs. The planned clinical trial will test Gilead’s TLR7 agonist in combination with Aelix’s T-cell vaccine. 

Novartis inks $2.1B Endocyte buyout, furthering radiotherapy push

Published: Thu, 18 Oct 2018 09:55:05 +0000
Novartis has struck a $2.1 billion (€1.8 billion) deal to acquire Endocyte. The deal caps off a whirlwind year for Endocyte, which licensed the cancer drug that caught Novartis’ eye for $12 million just 12 months ago.
Displaying results 1-3 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top